The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease

被引：0
|
作者：
Dignass, A. U. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Freudensprung, U. [4 ]
Addison, J. [5 ]
机构：
[1] Goethe Univ, Dept Med, Agaples Markus Hospital, Frankfurt, Germany
[2] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Gastroenter, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[3] Fdn Casa Sollievo della Sofferenza, IRCCS San Giovanni Rotondo, Div Gastroenterol, Puglia, Italy
[4] Biogen Int GmbH, Med Data Sci & Analyt MDSA Biosimilars, Baar, Switzerland
[5] Biogen Biosimilars Unit, Med, Baar, Switzerland
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P434
引用
收藏
页码：I418 / I418
页数：1
相关论文
共 50 条
  • [41] Real-World Outcomes of a Mandatory Adalimumab Non-Medical Biosimilar Switch for Patients With Inflammatory Bowel Disease: A Single Center Retrospective Study
    Hoang, Thomas
    Chen Kiow, Jeremy Liu
    Bedi, Harjot
    Ardekani, Zhina Majdzadeh
    Rosenfeld, Daniel
    Reise-Filteau, Marica
    Bressler, Brian
    Leung, Yvette
    Rosenfeld, Greg
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S748 - S749
  • [42] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Sitek-Ziolkowska, Karina
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Zhdan, Vyacheslav
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study (vol 11, pg 573, 2024)
    Fautrel, Bruno
    Bouhnik, Yoram
    Salliot, Carine
    Carbonnel, Franck
    Fumery, Mathurin
    Bernardeau, Christophe
    Maugars, Yves
    Flamant, Mathurin
    Coury, Fabienne
    Braithwaite, Ben
    Hateb, Salima
    Addison, Janet
    PERFUSE Investigators
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 163 - 164
  • [44] Real World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Study
    Yarur, Andres
    Bressler, Brian
    Brett, Neil
    Bassel, Marielle
    Adsul, Shashi
    Kamble, Pravin
    Mantzaris, Gerassimos J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S627 - S628
  • [45] SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY
    Schmalzing, M.
    Askari, A.
    Sheeran, T.
    Walsh, D.
    De Toro Santos, J.
    Vazquez Perez-Coleman, J. C.
    Both, C.
    Furlan, F.
    Hachaichi, S.
    Kellner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 540 - 540
  • [46] SECONDARY EFFICACY RESULTS UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMIAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M. C.
    Baranauskaite, A.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 231 - 231
  • [47] EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
    Parisi, S.
    Becciolini, A.
    Ditto, M. C.
    Ariani, A.
    Ianniello, A.
    Priora, M.
    Paroli, M.
    Realmuto, C.
    Peroni, C. L.
    Di Vittorio, C. M. Centanaro
    Degiovanni, R.
    Lagana, A.
    Fusaro, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1295 - 1296
  • [48] A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease
    Manuel Navas-Lopez, Victor
    Pujol Muncunill, Gemma
    Llerena, Enrique
    Naval Rubio, Maria
    Gil-Ortega, David
    Varea-Calderon, Vicente
    Sierra Salinas, Carlos
    Martin-de-Carpi, Javier
    ANALES DE PEDIATRIA, 2018, 88 (02): : 89 - 99
  • [49] Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea
    Yu, Jongwook
    Shin, Sung Jae
    Park, Yune-Jung
    Kim, Hyung Wook
    Lee, Bo-In
    Ye, Byong Duk
    Kim, Geun-Tae
    Kim, Sung Kook
    Kim, Joo Sung
    Kim, Young-Ho
    Jeong, Seonjeong
    Cheon, Jae Hee
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [50] Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
    Jongwook Yu
    Sung Jae Shin
    Yune-Jung Park
    Hyung Wook Kim
    Bo-In Lee
    Byong Duk Ye
    Geun-Tae Kim
    Sung Kook Kim
    Joo Sung Kim
    Young-Ho Kim
    Seonjeong Jeong
    Jae Hee Cheon
    BMC Gastroenterology, 23
12345